These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38454386)

  • 1. Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.
    Kang D; Wang C; Han Z; Zheng L; Guo W; Fu F; Qiu L; Han X; He J; Li L; Chen J
    BMC Cancer; 2024 Mar; 24(1):318. PubMed ID: 38454386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining the guidelines and multiphoton imaging methods to improve the prognostic value of tumor-infiltrating lymphocytes in breast cancer.
    He J; Kang D; Xu M; Han Z; Guo W; Fu F; Qiu L; Zheng L; Xi G; Wang W; Ren W; Han X; Tu H; Li L; Wang C; Chen J
    J Biophotonics; 2023 Jul; 16(7):e202300060. PubMed ID: 36965036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumour-infiltrating lymphocytes based on the evaluation of frequency in patients with oestrogen receptor-positive breast cancer.
    He J; Fu F; Wang W; Xi G; Guo W; Zheng L; Ren W; Qiu L; Huang X; Wang C; Li L; Kang D; Chen J
    Eur J Cancer; 2021 Sep; 154():217-226. PubMed ID: 34293665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
    Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M
    Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of E26 transformation specific-1 (ETS-1) in tumour-infiltrating lymphocytes (TILs) is adverse prognostic factor in invasive breast cancer.
    Puzovic V; Jakic-Razumovic J
    Breast Dis; 2021; 40(1):25-31. PubMed ID: 33459689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging and molecular features associated with tumor-infiltrating lymphocytes in breast cancer.
    Wu J; Li X; Teng X; Rubin DL; Napel S; Daniel BL; Li R
    Breast Cancer Res; 2018 Sep; 20(1):101. PubMed ID: 30176944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Feb; 9(1):1583. PubMed ID: 30733496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
    Schiza A; Thurfjell V; Stenmark Tullberg A; Olofsson H; Lindberg A; Holmberg E; Bremer T; Micke P; Karlsson P; Wärnberg F; Strell C
    Eur J Cancer; 2022 Jun; 168():128-137. PubMed ID: 35236568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.
    Droeser R; Zlobec I; Kilic E; Güth U; Heberer M; Spagnoli G; Oertli D; Tapia C
    BMC Cancer; 2012 Apr; 12():134. PubMed ID: 22471961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of tumor lymphocyte infiltration with clinicopathological factors and survival in breast cancer.
    Huszno J; Nożyńska EZ; Lange D; Kołosza Z; Nowara E
    Pol J Pathol; 2017; 68(1):26-32. PubMed ID: 28547977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-infiltrating lymphocytes (TILs)/volume and prognosis: The value of TILs for survival in HER2 and TN breast cancer patients treated with chemotherapy.
    Okcu O; Öztürk SD; Öztürk Ç; Şen B; Yasin Aİ; Bedir R
    Ann Diagn Pathol; 2022 Jun; 58():151930. PubMed ID: 35245821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-Infiltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma.
    Vaziri Fard E; Ali Y; Wang XI; Saluja K; H Covinsky M; Wang L; Zhang S
    Am J Clin Pathol; 2019 Oct; 152(5):656-665. PubMed ID: 31305879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast.
    Toss MS; Miligy I; Al-Kawaz A; Alsleem M; Khout H; Rida PC; Aneja R; Green AR; Ellis IO; Rakha EA
    Mod Pathol; 2018 Aug; 31(8):1226-1236. PubMed ID: 29559742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
    Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
    Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
    Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
    Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients.
    Ahmadvand S; Faghih Z; Montazer M; Safaei A; Mokhtari M; Jafari P; Talei AR; Tahmasebi S; Ghaderi A
    Cell Oncol (Dordr); 2019 Jun; 42(3):343-356. PubMed ID: 30825183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.
    Wang K; Xu J; Zhang T; Xue D
    Oncotarget; 2016 Jul; 7(28):44288-44298. PubMed ID: 27329588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-infiltrating lymphocytes in ductal carcinoma in situ (DCIS)-assessment with three different methodologies and correlation with Oncotype DX DCIS Score.
    Komforti M; Badve SS; Harmon B; Lo Y; Fineberg S
    Histopathology; 2020 Nov; 77(5):749-759. PubMed ID: 32557780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
    Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
    Blok EJ; Engels CC; Dekker-Ensink G; Meershoek-Klein Kranenbarg E; Putter H; Smit VTHBM; Liefers GJ; Morden JP; Bliss JM; Coombes RC; Bartlett JMS; Kroep JR; van de Velde CJH; Kuppen PJK
    Breast Cancer Res Treat; 2018 Aug; 171(1):65-74. PubMed ID: 29766362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.